Clinical Trial Transparency — Antidote to Weaker Off-Label-Promotion Rules? — NEJM

Retweeted NEJM (@NEJM): Need for clin trial transparency more urgent as drug cos say off-label promotion rules violate 1st Amend.: Outterson. http://t.co/APvB3ywofP

via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/APvB3ywofP